The U.S. Congress greenlit a historic $315 million in federal ALS research funding for 2026 amid Rare Disease Month, spotlighting biotech progress like VectorY Therapeutics' first patient dosing in ...

Experimental therapy RT1999 will soon be tested in the UK EXPERTS-ALS platform trial designed to rapidly screen potential ALS treatments.

Researchers at the University of Alabama at Birmingham are working to better understand ALS and find new ways to slow or stop the disease.

In March 2024, Kayla Gonzalez started having an odd sensation behind her right kneecap. At first, she didn’t think much of it. Then, the feeling started to spread. Soon, she had weakness in her calf, ...

Keros Therapeutics will use the Massachusetts General Hospital MyMatch program to design a clinical trial testing rinvatercept for ALS.

Highlights: First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS; Approximately 160 particip ...

The ALS Association and the ALS Finding a Cure Foundation are pleased to announce $3 million in funding for two new Phase II clinical studies through the ALS Accelerated Therapeutics (ALS ACT) ...

WASHINGTON — The Food and Drug Administration meets this week to consider approval of an experimental treatment for Lou Gehrig’s disease, the culmination of a yearslong lobbying effort by patients ...

Following a battle with ALS, Eric Dane, an actor widely known for his role as Dr. Mark Sloan, aka "McSteamy," in ABC's "Grey's Anatomy," died Feb. 19. He was 53 years old. The news of his death comes ...